将要求肢端肥大症患者终身监测生长激素和胰岛素样生长因子 1 (IGF-1) 水平。一旦初始治疗干预（手术、药物治疗及放疗，视需要而定）已矫正或显著性改善疾病状况，则推荐定期监测疾病相关的指标。也需要监测和治疗肢端肥大症并发症。[14]Katznelson L, Atkinson JL, Cook DM, at al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly - 2011 update. Endocr Pract. 2011;17(Suppl 4):1-44.https://www.aace.com/files/acromegaly-guidelines.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/21846616?tool=bestpractice.com[51]Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054-4058.http://press.endocrine.org/doi/full/10.1210/jc.2002-011841http://www.ncbi.nlm.nih.gov/pubmed/12213843?tool=bestpractice.com
[Figure caption and citation for the preceding image starts]: 肢端肥大症持续监测建议由 BMJ 根据作者的内容创制 [Citation ends].
